Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
85 | Publisher: Global Markets Direct
Industry: Medical Devices | Report Format: Electronic (PDF)
Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2015', provides an overview of the Allergic Rhino-Conjunctivitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhino-Conjunctivitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhino-Conjunctivitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhino-Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhino-Conjunctivitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhino-Conjunctivitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of table 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Allergic Rhino-Conjunctivitis Overview 8 Therapeutics Development 9 Pipeline Products for Allergic Rhino-Conjunctivitis - Overview 9 Pipeline Products for Allergic Rhino-Conjunctivitis - Comparative Analysis 10 Allergic Rhino-Conjunctivitis - Therapeutics under Development by Companies 11 Allergic Rhino-Conjunctivitis - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Allergic Rhino-Conjunctivitis - Products under Development by Companies 15 Allergic Rhino-Conjunctivitis - Companies Involved in Therapeutics Development 17 ALK-Abello A/S 17 Allergopharma Joachim Ganzer KG 18 Allergy Therapeutics plc 19 Anergis SA 20 Bial - Portela & Ca, S.A. 21 BioTech Tools s.a. 22 Circassia Pharmaceuticals plc 23 Greer Laboratories, Inc. 24 HAL Allergy BV 25 Immunomic Therapeutics, Inc. 26 Laboratorios LETI S.L. 27 Stallergenes S.A. 28 Allergic Rhino-Conjunctivitis - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Combination Products 30 Assessment by Target 31 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 Acaroid - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 AL-0704rP - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ALK Birch Pollen Vaccine - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Allergovac - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 AllerT - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Avanz Cupressus Immunotherapy for Allergic Rhino-Conjunctivitis - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Avanz Phleum Pratense - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Avanz Salsola Immunotherapy for Allergic Rhino-Conjunctivitis - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Depigoid Birch - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Dermatophagoides Pteronyssinus Allergen Extract - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 gpASIT + TM - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Grass Pollen Allergoid - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Grass-SPIRE - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 House Dust Mite-SPIRE - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 JRC2-LAMP-vax - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 MK-8237 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Olea Europaea Pollen Extract - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Pollinex Quattro Grass - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Ragweed Pollen Extract - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 rBet v1 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 rBet v1-FV - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 rPhleum - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Allergic Rhino-Conjunctivitis - Recent Pipeline Updates 68 Allergic Rhino-Conjunctivitis - Dormant Projects 76 Allergic Rhino-Conjunctivitis - Discontinued Products 77 Allergic Rhino-Conjunctivitis - Product Development Milestones 78 Featured News & Press Releases 78 Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen 78 May 18, 2014: BioTech Tools will be present at the EAACI congress 79 Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology 80 Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics 81 Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites 82 Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA 82 Appendix 84 Methodology 84 Coverage 84 Secondary Research 84 Primary Research 84 Expert Panel Validation 84 Contact Us 84 Disclaimer 85
List of Tables Number of Products under Development for Allergic Rhino-Conjunctivitis, H1 2015 9 Number of Products under Development for Allergic Rhino-Conjunctivitis - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 12 Comparative Analysis by Late Stage Development, H1 2015 13 Comparative Analysis by Clinical Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Products under Development by Companies, H1 2015 (Contd..1) 16 Allergic Rhino-Conjunctivitis - Pipeline by ALK-Abello A/S, H1 2015 17 Allergic Rhino-Conjunctivitis - Pipeline by Allergopharma Joachim Ganzer KG, H1 2015 18 Allergic Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics plc, H1 2015 19 Allergic Rhino-Conjunctivitis - Pipeline by Anergis SA, H1 2015 20 Allergic Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca, S.A., H1 2015 21 Allergic Rhino-Conjunctivitis - Pipeline by BioTech Tools s.a., H1 2015 22 Allergic Rhino-Conjunctivitis - Pipeline by Circassia Pharmaceuticals plc, H1 2015 23 Allergic Rhino-Conjunctivitis - Pipeline by Greer Laboratories, Inc., H1 2015 24 Allergic Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H1 2015 25 Allergic Rhino-Conjunctivitis - Pipeline by Immunomic Therapeutics, Inc., H1 2015 26 Allergic Rhino-Conjunctivitis - Pipeline by Laboratorios LETI S.L., H1 2015 27 Allergic Rhino-Conjunctivitis - Pipeline by Stallergenes S.A., H1 2015 28 Assessment by Monotherapy Products, H1 2015 29 Assessment by Combination Products, H1 2015 30 Number of Products by Stage and Target, H1 2015 31 Number of Products by Stage and Route of Administration, H1 2015 33 Number of Products by Stage and Molecule Type, H1 2015 35 Allergic Rhino-Conjunctivitis Therapeutics - Recent Pipeline Updates, H1 2015 68 Allergic Rhino-Conjunctivitis - Dormant Projects, H1 2015 76 Allergic Rhino-Conjunctivitis - Discontinued Products, H1 2015 77
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.